Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
| Language | Translation |
|---|---|
English
|
Psoriatic spondylitis |
French
|
Spondylite psoriasique (L40.5) |
| Level | Code | Title | |
|---|---|---|---|
| 1 | XIII | Diseases of the musculoskeletal system and connective tissue | |
| 2 | M05-M14 | Inflammatory polyarthropathies | |
| 3 | M07 | Psoriatic and enteropathic arthropathies | |
| 4 | M07.2 | Psoriatic spondylitis |
| Active Ingredient | Description | |
|---|---|---|
| Apremilast |
Apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. |
|
| Tofacitinib |
Tofacitinib is a potent, selective inhibitor of the JAK family. In human cells, tofacitinib preferentially inhibits signalling by heterodimeric cytokine receptors that associate with JAK3 and/or JAK1. Inhibition of JAK1 and JAK3 by tofacitinib attenuates signalling of interleukins and type I and type II interferons, which will result in modulation of the immune and inflammatory response. |
